.Attributes Medicine, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA study, after a typical consequence of 11 months, clients along with metastatic gastrointestinal tumors who received biomarker-matched treatments based upon flowing lump DNA profiling showed a greater scientific perk than those acquiring incomparable treatment.